Pharma BD Deal Intelligence
A $1.75B biopharma acquisition where Ipsen bets on navtemadlin, an oral MDM2 inhibitor, to boost its hemato-oncology pipeline in myelofibrosis. With only $450 million paid upfront and the rest tied to Phase 3 data due in 2027, this is a slow-burn wager on unproven efficacy.
Late-stage myelofibrosis asset deepening Ipsen hemato-oncology
Full analysis, sources & comparables →On June 29, 2026, Ipsen entered a definitive merger agreement to acquire US hemato-oncology biotech Kartos Therapeutics for $450 million upfront at closing plus up to $1.3 billion in milestones (regulatory-approval and sales-based), for total potential consideration of up to ~$1.75 billion. The deal adds navtemadlin (KRT-232), an investigational oral MDM2 inhibitor designed to restore p53 tumor-suppressor function, being evaluated as add-on to ruxolitinib in myelofibrosis patients with suboptimal response (Phase 3 POIESIS; top-line data expected 2027). The transaction is expected to close by end of Q3 2026 and to be accretive to Ipsen core operating income from 2029.
Navtemadlin (KRT-232) is an oral MDM2 inhibitor that restores the natural tumor-suppressing function of p53. It is being developed as an add-on to ruxolitinib (current standard of care) in myelofibrosis patients with a suboptimal response, in the Phase 3 POIESIS trial, with top-line data expected in 2027. Ipsen gains a late-stage hemato-oncology asset with potential in additional p53-wild-type malignancies.
Ipsen agrees to acquire Kartos for $450M upfront + up to $1.3B milestones (~$1.75B total), adding navtemadlin (MDM2i) in myelofibrosis. Close expected end of Q3 2026.
A Phase 3 MDM2 asset with meaningful upfront ($450M); value is back-half-weighted on POIESIS success (2027 data) and regulatory/sales milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Kartos Therapeutics, Inc. (this deal) | 2026 | $1.8B | 68 |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
| Ipsen S.A. / Simcere Zaiming Pharmaceutical Co., Ltd. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2026 deals · Ipsen S.A. deals · Oncology deals